CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 143 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $592 | -100.0% | 344,169 | +38.1% | 0.06% | -54.3% |
| Q3 2021 | $1,268,000 | +756.8% | 249,146 | +1204.9% | 0.13% | +416.0% |
| Q1 2021 | $148,000 | -29.2% | 19,093 | -40.1% | 0.02% | -26.5% |
| Q4 2020 | $209,000 | +11.2% | 31,854 | +12.8% | 0.03% | +9.7% |
| Q3 2020 | $188,000 | -44.5% | 28,251 | -30.6% | 0.03% | -83.6% |
| Q2 2020 | $339,000 | -28.0% | 40,735 | -33.7% | 0.19% | +60.2% |
| Q1 2020 | $471,000 | -51.3% | 61,416 | -47.3% | 0.12% | +4.4% |
| Q4 2019 | $968,000 | +68.1% | 116,516 | +49.4% | 0.11% | +44.9% |
| Q3 2019 | $576,000 | -21.8% | 77,997 | +18.7% | 0.08% | -6.0% |
| Q2 2019 | $737,000 | +92.4% | 65,695 | +84.2% | 0.08% | +112.8% |
| Q1 2019 | $383,000 | -26.9% | 35,658 | +2.8% | 0.04% | -35.0% |
| Q4 2018 | $524,000 | -18.9% | 34,700 | -0.6% | 0.06% | +66.7% |
| Q3 2018 | $646,000 | -43.5% | 34,900 | -30.2% | 0.04% | -36.8% |
| Q2 2018 | $1,143,000 | +355.4% | 50,000 | +466.1% | 0.06% | +338.5% |
| Q1 2018 | $251,000 | – | 8,833 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,500,000 | $7,635,000 | 1.78% |
| Altium Capital Management LP | 1,233,642 | $6,279,000 | 1.65% |
| RA Capital Management | 3,500,000 | $17,815,000 | 0.25% |
| Soleus Capital Management, L.P. | 261,050 | $1,329,000 | 0.21% |
| Affinity Asset Advisors, LLC | 125,000 | $636,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,078,103 | $5,488,000 | 0.16% |
| Point72 Asset Management, L.P. | 6,303,025 | $32,082,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 249,146 | $1,268,000 | 0.13% |
| Candriam S.C.A. | 3,305,940 | $16,826,000 | 0.11% |
| RTW INVESTMENTS, LP | 1,400,939 | $7,131,000 | 0.11% |